Abstract
Background: Erectile dysfunction (ED) affects 30 million men in the US with a decrease in quality of life. Thirty percent of hypertensive men suffer from ED.
Objective: This review will debate the interplay between hypertension and ED, discovering novel insights concerning hypertension-linked ED, as well as the influence of antihypertensive medications on patients with ED.
Method: Total number of records screened from PubMed yielded by the search which performed from January 2000 - June 2018.
Results: Hypertension can cause ED as a consequence of high blood pressure or antihypertensive treatment. Both hypertension and ED have endothelial dysfunction as a common base mechanism, which can lead to an increase in vascular smooth muscle contraction. Also, some phosphodiesterase (PDE)-5 inhibitors used to treat ED can recover blood pressure.
Conclusion: Understanding of common mechanisms involved in ED accompanied with hypertension and the research on antihypertensive drugs that impact ED will bring important approaches for identifying novel therapeutic strategies that will improve quality of life in patients with these conditions.
Keywords: Antihypertensive treatment, endothelial dysfunction, erectile dysfunction, hypertension, phosphodiesterase-5 inhibitors, high blood pressure.
Current Pharmaceutical Design
Title:Management of Erectile Dysfunction: An Under-Recognition of Hypertension
Volume: 24 Issue: 30
Author(s): Gokhan Koroglu, Ecem Kaya-Sezginer, Didem Yilmaz-Oral and Serap Gur*
Affiliation:
- Department of Biochemistry and Pharmacology, Faculty of Pharmacy, Ankara University, Ankara,Turkey
Keywords: Antihypertensive treatment, endothelial dysfunction, erectile dysfunction, hypertension, phosphodiesterase-5 inhibitors, high blood pressure.
Abstract: Background: Erectile dysfunction (ED) affects 30 million men in the US with a decrease in quality of life. Thirty percent of hypertensive men suffer from ED.
Objective: This review will debate the interplay between hypertension and ED, discovering novel insights concerning hypertension-linked ED, as well as the influence of antihypertensive medications on patients with ED.
Method: Total number of records screened from PubMed yielded by the search which performed from January 2000 - June 2018.
Results: Hypertension can cause ED as a consequence of high blood pressure or antihypertensive treatment. Both hypertension and ED have endothelial dysfunction as a common base mechanism, which can lead to an increase in vascular smooth muscle contraction. Also, some phosphodiesterase (PDE)-5 inhibitors used to treat ED can recover blood pressure.
Conclusion: Understanding of common mechanisms involved in ED accompanied with hypertension and the research on antihypertensive drugs that impact ED will bring important approaches for identifying novel therapeutic strategies that will improve quality of life in patients with these conditions.
Export Options
About this article
Cite this article as:
Koroglu Gokhan , Kaya-Sezginer Ecem , Yilmaz-Oral Didem and Gur Serap *, Management of Erectile Dysfunction: An Under-Recognition of Hypertension, Current Pharmaceutical Design 2018; 24 (30) . https://dx.doi.org/10.2174/1381612824666180828104350
DOI https://dx.doi.org/10.2174/1381612824666180828104350 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hepatoma Derived Growth Factor is a Nuclear Targeted Mitogen
Current Drug Targets Treatment of Cardiovascular Risk Factors in Women
Current Medicinal Chemistry The Panomics Approach in Neurodegenerative Disorders
Current Medicinal Chemistry Editorial (Hot Topic: Update on Treatment Strategies in Patients with Non-alcoholic Fatty Liver Disease)
Current Pharmaceutical Design Effects of Diabetes on Murine Lipoproteins and Vascular Disease
Current Drug Targets Effect of Aluminium Chloride Concentration on Diltiazem Hydrochloride Release from pH-sensitive Hydrogel Beads Composed of Hydrolyzed Grafted k-Carrageenan and Sodium Alginate
Current Chemical Biology Consequences of Type 1 and 2 Diabetes Mellitus on the Cardiovascular Regulation During Exercise: A Brief Review
Current Diabetes Reviews The Socioeconomic Effects of Uncontrolled Hypertension
Current Vascular Pharmacology Life-Threatening Respiratory Syncytial Virus Disease in Children
Current Respiratory Medicine Reviews Statins in Diabetes Mellitus
Current Pharmaceutical Design Arterial Stiffness: A Novel Cardiovascular Risk Factor in Kidney Disease Patients
Current Vascular Pharmacology Role of Calabrian Black Rice in Metabolic Syndrome: In vitro Evaluation of Oryza sativa L. Indica Biological Properties
Current Nutrition & Food Science The Dual Role of Free Fatty Acid Signaling in Inflammation and Therapeutics
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Vascular Inflammation and Atherosclerosis: The Role of Estrogen Receptors
Current Medicinal Chemistry Oxidative Stress and Vascular Disease
Current Hypertension Reviews Anticoagulant Therapy in Pregnant Patients with Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Novel Inflammatory Biomarkers in Cardiovascular Disease: From Molecular Mechanisms to Therapeutic Targets (Part-II))
Current Medicinal Chemistry Variability in Response to Cardiovascular Drugs
Current Clinical Pharmacology May Oxygen-Ozone Therapy Improves Cardiovascular Disorders?
Cardiovascular & Hematological Disorders-Drug Targets The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
Current Pharmaceutical Design